Protein kinase C beta type II (PKC beta 2)

Protein kinase C beta 2 (PKCβII) is a calcium-dependent serine/threonine kinase belonging to the conventional protein kinase C (cPKC) subfamily [1.2.1]. Encoded by the PRKCB gene, it is a splice variant that is activated by diacylglycerol (DAG) and calcium ions to regulate critical signaling pathways [1.1.1, 1.2.1]. PKCβII is involved in a wide range of biological functions, including B-cell activation, endothelial cell proliferation, and insulin signaling [1.1.2, 1.3.1]. In oncology, its overexpression is associated with poor prognosis in diffuse large B-cell lymphoma (DLBCL) and promotes angiogenesis and tumor growth in glioblastoma and colorectal cancer [1.1.1, 1.2.2]. Additionally, PKCβII activation by hyperglycemia is a key driver of diabetic microvascular complications, such as retinopathy and nephropathy [1.4.1, 1.4.3]. Therapeutic efforts have focused on small-molecule inhibitors like enzastaurin and ruboxistaurin, which competitively inhibit the ATP-binding site of the kinase domain [1.1.1, 1.4.1]. However, clinical development has been hindered by limited efficacy in phase III trials and challenges in achieving high isoform selectivity [1.2.3, 1.4.1]. Beyond cancer and diabetes, the target is also investigated for its roles in cardiovascular disease and neurodegeneration [1.2.3, 1.3.2]. The protein also serves as a receptor for phorbol esters, which are potent tumor promoters [1.2.1, 1.3.1].

Other names

PRKCBPRKCB2PKC-beta-2PKC-beta-IIProtein kinase C beta 2

ATP-competitive inhibition of the kinase domain, which prevents the phosphorylation of downstream substrates such as GSK3β, Akt, and S6 ribosomal protein, thereby inhibiting cell proliferation and angiogenesis [1.1.1, 1.4.1].